Τίτλος:
Strategies to control hepatitis B: Public policy, epidemiology, vaccine
and drugs
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
The last 50 years of hepatitis B research has resulted in the
development of effective screening assays for surveillance, vaccines for
prevention and antiviral drugs that significantly improve patient
clinical outcomes. Not surprisingly then, the global epidemiology of
hepatitis B virus (HBV) is set to change dramatically over the next
decade. For example, the success and the high coverage of universal HBV
vaccination and the ageing cohorts of patients with chronic hepatitis B
(CHB) will result in reductions of incidence and prevalence of chronic
hepatitis, cirrhosis and probably hepatocellular carcinoma. This will be
further accelerated by the impressive progress in the treatment outcomes
for patients with CHB. In spite of this success, challenges remain, such
as planning for the impact of migration from countries with high
prevalence rates to those countries with low rates of HBV infection. The
recent establishment of the World Health Organisation Global Hepatitis
Program with the provision of a framework for global action has become
the cornerstone for all countries to now frame their own particular
national responses to control hepatitis B. An effective policy framework
can prevent new infections, ensure people can access clinical care, and
in doing so reduce the burden of infection at an individual, country and
regional level. These developments present a real opportunity to reduce
the significant, social and economic burden of global hepatitis B,
ultimately the critical next steps to render the world hepatitis B free.
(C) 2015 European Association for the Study of the Liver. Published by
Elsevier B.V. All rights reserved.
Συγγραφείς:
Locarnini, Stephen
Hatzakis, Angelos
Chen, Ding-Shinn
Lok,
Anna
Περιοδικό:
WORLD JOURNAL OF HEPATOLOGY
Λέξεις-κλειδιά:
Epidemiology; Prevention; Hepatitis B vaccine; Acute hepatitis B;
Chronic hepatitis B; Treatment; Chronic liver disease; Hepatocellular
carcinoma; Public policy; WHO
DOI:
10.1016/j.jhep.2015.01.018
